Literature DB >> 19269120

X-linked adrenoleukodystrophy: clinical course and minimal incidence in South Brazil.

Laura Bannach Jardim1, Andrew Chaves Feitosa da Silva, Deborah Blank, Maria Mercedes Villanueva, Luisa Renck, Mariana La Bella Costa, Carmen Regla Vargas, Marion Deon, Daniel la M Coelho, Leonardo Vedolin, Cláudio Galvão de Castro, Lauro Gregianin, Carmem Bonfim, Roberto Giugliani.   

Abstract

UNLABELLED: X-linked adenoleukodystrophy is a genetic disease that affects the degradation of very long-chain fatty acids. In male patients, common pictures are the cerebral form (CALD), myeloneuropathy (AMN), and Addison-only.
OBJECTIVE: To describe the clinical course of affected male patients from South Brazil between 1993 and 2007.
METHODS: Affected male patients and their maternal lineages were studied from a clinical, neurological and biochemical standpoint.
RESULTS: Eighty-three male patients from 30 families were biochemically evaluated: 51 were affected. 27/51 (54%) presented the cerebral form; 11/51 had AMN (22%); 5 had Addison-only (10%), and 8 (16%) were asymptomatic. Between 2002 and 2006, the minimal incidence was 1:35,000 males in our State (South Brazil). Forty-three affected individuals were followed for 5.4+/-3.7 years. Of 10 boys detected at early stages, three developed CALD. These three boys and another five CALD at baseline were referred to hematopoietic stem cell transplantation. Seven transplants were carried out, 5 with good clinical evolution after 2.2 years post-transplant. The non-transplanted case was later defined as a stable cerebral form. DISCUSSION: Among the present families, the observed cases were comparable to the 50% expected by Mendelian segregation. Based on the natural history, the number of cases that developed CALD was similar to the expected. Transplants were successful in 70% of cases. The occurrence of a stable cerebral form pointed to an urgent need for better markers of active cerebral disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269120     DOI: 10.1016/j.braindev.2009.02.002

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  6 in total

1.  Progression rate of myelopathy in X-linked adrenoleukodystrophy heterozygotes.

Authors:  Clarissa Troller Habekost; Fernanda Santos Pereira; Carmen Regla Vargas; Daniella Moura Coelho; Vitor Torrez; Jean Pierre Oses; Luis Valmor Portela; Pedro Schestatsky; Vitor Torres Felix; Ursula Matte; Vanessa Leotti Torman; Laura Bannach Jardim
Journal:  Metab Brain Dis       Date:  2015-04-30       Impact factor: 3.584

Review 2.  Therapeutic strategies in adrenoleukodystrophy.

Authors:  Bela R Turk; Ann B Moser; Ali Fatemi
Journal:  Wien Med Wochenschr       Date:  2017-05-10

3.  Eight novel mutations in the ABCD1 gene and clinical characteristics of 25 Chinese patients with X-linked adrenoleukodystrophy.

Authors:  Shan-Shan Chu; Jun Ye; Hui-Wen Zhang; Lian-Shu Han; Wen-Juan Qiu; Xiao-Lan Gao; Xue-Fan Gu
Journal:  World J Pediatr       Date:  2015-10-11       Impact factor: 2.764

4.  Mutations, clinical findings and survival estimates in South American patients with X-linked adrenoleukodystrophy.

Authors:  Fernanda dos Santos Pereira; Ursula Matte; Clarissa Troller Habekost; Raphael Machado de Castilhos; Antonette Souto El Husny; Charles Marques Lourenço; Angela M Vianna-Morgante; Liane Giuliani; Marcial Francis Galera; Rachel Honjo; Chong Ae Kim; Juan Politei; Carmen Regla Vargas; Laura Bannach Jardim
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

Review 5.  The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis.

Authors:  Christoph Wiesinger; Florian S Eichler; Johannes Berger
Journal:  Appl Clin Genet       Date:  2015-05-02

6.  Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme.

Authors:  Alice Bessey; James B Chilcott; Joanna Leaviss; Anthea Sutton
Journal:  Orphanet J Rare Dis       Date:  2018-10-11       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.